SEGLENTIS Drug Patent Profile
✉ Email this page to a colleague
When do Seglentis patents expire, and when can generic versions of Seglentis launch?
Seglentis is a drug marketed by Kowa Pharms and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and five patent family members in thirty-five countries.
The generic ingredient in SEGLENTIS is celecoxib; tramadol hydrochloride. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the celecoxib; tramadol hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seglentis
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 19, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SEGLENTIS?
- What are the global sales for SEGLENTIS?
- What is Average Wholesale Price for SEGLENTIS?
Summary for SEGLENTIS
| International Patents: | 105 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for SEGLENTIS |
| What excipients (inactive ingredients) are in SEGLENTIS? | SEGLENTIS excipients list |
| DailyMed Link: | SEGLENTIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SEGLENTIS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SEGLENTIS
| Drug Class | Nonsteroidal Anti-inflammatory Drug Opioid Agonist |
| Mechanism of Action | Cyclooxygenase Inhibitors Full Opioid Agonists |
US Patents and Regulatory Information for SEGLENTIS
SEGLENTIS is protected by seven US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLENTIS is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEGLENTIS
Co-crystals of tramadol and coxibis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Co-crystals of tramadol and coxibs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting SEGLENTIS
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SEGLENTIS
When does loss-of-exclusivity occur for SEGLENTIS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 9008
Patent: CO-CRISTALES DE TRAMADOL Y COXIBS, PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09304235
Patent: Co-crystals of tramadol and NSAIDs
Estimated Expiration: ⤷ Sign Up
Patent: 10306168
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0920358
Patent: cocristais de tramadol e insaids
Estimated Expiration: ⤷ Sign Up
Patent: 2012005011
Patent: cocristais de tramadol e coxibis
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 37754
Patent: CO-CRISTAUX DE TRAMADOL ET D'AINS (CO-CRYSTALS OF TRAMADOL AND NSAIDS)
Estimated Expiration: ⤷ Sign Up
Patent: 71665
Patent: CO-CRISTAUX DE TRAMADOL ET DE COXIBS (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2186465
Patent: Co-crystals of tramadol and nsaids
Estimated Expiration: ⤷ Sign Up
Patent: 2573825
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷ Sign Up
Patent: 4817501
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Patent: 4844513
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 11248
Patent: COCRISTALES DE TRAMADOL Y COXIBS
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0130316
Estimated Expiration: ⤷ Sign Up
Patent: 0161526
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 13956
Estimated Expiration: ⤷ Sign Up
Patent: 18374
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 49238
Estimated Expiration: ⤷ Sign Up
Patent: 88169
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12011734
Patent: COCRISTALES DE TRAMADOL Y COXIBS
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 77215
Patent: Co-cristaux de tramadol et NSAID (Co-crystals of tramadol and NSAIDs)
Estimated Expiration: ⤷ Sign Up
Patent: 49238
Patent: CO-CRISTAUX DE TRAMADOL ET NSAID (CO-CRYSTALS OF TRAMADOL AND NSAIDS)
Estimated Expiration: ⤷ Sign Up
Patent: 88169
Patent: CO-CRISTAUX DE TRAMADOL ET NSAID (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷ Sign Up
Patent: 86432
Patent: Co-cristaux de Tramadol et NSAID tels que des Coxibs (Co-crystals of Tramadol and NSAIDs like Coxibs)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 73380
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 30976
Estimated Expiration: ⤷ Sign Up
India
Patent: 35DEN2012
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 1785
Patent: קו-גבישים של טרמדול ונפרוקסן (Co-crystals of tramadol and naproxen)
Estimated Expiration: ⤷ Sign Up
Patent: 8256
Patent: קו-גביש של טרמדול הידרוכלוריד רצמי וסלקוקסיב (Co-crystal of (rac) tramadol hcl and celecoxib)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 99564
Estimated Expiration: ⤷ Sign Up
Patent: 45830
Estimated Expiration: ⤷ Sign Up
Patent: 12505847
Estimated Expiration: ⤷ Sign Up
Patent: 13507402
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 49238
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6285
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 6318
Patent: CO-CRISTALES DE TRAMADOL Y NSAIDS. (CO-CRYSTALS OF TRAMADOL AND NSAIDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 11003612
Patent: CO-CRISTALES DE TRAMADOL Y NSAIDS. (CO-CRYSTALS OF TRAMADOL AND NSAIDS.)
Estimated Expiration: ⤷ Sign Up
Patent: 12003050
Patent: CO-CRISTALES DE TRAMADOL Y COXIBS. (CO-CRYSTALS OF TRAMADOL AND COXIBS.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 742
Patent: بلورات متعددة ترامادول و كوكسيب
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1873
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDS
Estimated Expiration: ⤷ Sign Up
Patent: 8353
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 49238
Estimated Expiration: ⤷ Sign Up
Patent: 88169
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 49238
Estimated Expiration: ⤷ Sign Up
Patent: 88169
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 47830
Patent: СОКРИСТАЛЛЫ ТРАМАДОЛА И КОКСИБОВ (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷ Sign Up
Patent: 99717
Patent: СОКРИСТАЛЛИЧЕСКИЕ ФОРМЫ ТРАМАДОЛА И NSAID (CO-CRYSTALLINE FORMS OF TRAMADOL AND NSAID)
Estimated Expiration: ⤷ Sign Up
Patent: 11119608
Patent: СОКРИСТАЛЛИЧЕСКИЕ ФОРМЫ ТРАМАДОЛА И NSAID
Estimated Expiration: ⤷ Sign Up
Patent: 12120088
Patent: СОКРИСТАЛЛЫ ТРАМАДОЛА И КОКСИБОВ
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01300048
Patent: Cocristalli di tramadol e inibitori della cox-2
Estimated Expiration: ⤷ Sign Up
Patent: 01600439
Patent: CO-CRISTALLI DI TRAMADOLO E NSAID
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 8835
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 49238
Estimated Expiration: ⤷ Sign Up
Patent: 88169
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1102762
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDs
Estimated Expiration: ⤷ Sign Up
Patent: 1201892
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1471585
Estimated Expiration: ⤷ Sign Up
Patent: 1679400
Estimated Expiration: ⤷ Sign Up
Patent: 110069860
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDS
Estimated Expiration: ⤷ Sign Up
Patent: 120099212
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 02112
Estimated Expiration: ⤷ Sign Up
Patent: 03962
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 41630
Estimated Expiration: ⤷ Sign Up
Patent: 1116273
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 12000075
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 9534
Patent: СПІВКРИСТАЛИ ТРАМАДОЛУ І КОКСИБІВ (TRAMADOL AND COXIBES COCRYSTALLS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SEGLENTIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2013530952 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2010043412 | ⤷ Sign Up | |
| China | 102946871 | Pharmaceutical compositions of co-crystals of tramadol and coxibs | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEGLENTIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0731795 | 10075033 | Germany | ⤷ Sign Up | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
